OSI kept at outperform by Bear Stearns

OSI Pharmaceuticals Inc. was maintained at its outperform rating with a $40 price target by Bear Stearns analyst Akhtar Samad. The company's analyst day clarified OSI's strategy on Macugen and underscored the value in its pipeline, including new indications for Tarceva and OSI's diabetes franchise. Shares of the Melville, N.Y., biotechnology company were down 96 cents, or 2.90%, at $32.18 on volume of 1,301,482 shares versus the three-month running average of 1,719,410 shares. (Nasdaq: OSIP)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.